PL3532459T3 - Inhibitory lsd1 i ich zastosowania medyczne - Google Patents

Inhibitory lsd1 i ich zastosowania medyczne

Info

Publication number
PL3532459T3
PL3532459T3 PL17797805.3T PL17797805T PL3532459T3 PL 3532459 T3 PL3532459 T3 PL 3532459T3 PL 17797805 T PL17797805 T PL 17797805T PL 3532459 T3 PL3532459 T3 PL 3532459T3
Authority
PL
Poland
Prior art keywords
medical uses
lsd1 inhibitors
lsd1
inhibitors
medical
Prior art date
Application number
PL17797805.3T
Other languages
English (en)
Inventor
Francois BRUCELLE
Victor S. Gehling
Avinash KHANNA
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of PL3532459T3 publication Critical patent/PL3532459T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17797805.3T 2016-10-26 2017-10-26 Inhibitory lsd1 i ich zastosowania medyczne PL3532459T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413162P 2016-10-26 2016-10-26
US201662413166P 2016-10-26 2016-10-26
PCT/US2017/058405 WO2018081343A1 (en) 2016-10-26 2017-10-26 Lsd1 inhibitors and medical uses thereof

Publications (1)

Publication Number Publication Date
PL3532459T3 true PL3532459T3 (pl) 2024-06-24

Family

ID=60320993

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17797805.3T PL3532459T3 (pl) 2016-10-26 2017-10-26 Inhibitory lsd1 i ich zastosowania medyczne

Country Status (20)

Country Link
US (3) US10517849B2 (pl)
EP (1) EP3532459B1 (pl)
JP (1) JP7142633B2 (pl)
CN (1) CN109863137B (pl)
AU (1) AU2017348100B2 (pl)
CA (1) CA3039793A1 (pl)
DK (1) DK3532459T3 (pl)
ES (1) ES2961499T3 (pl)
FI (1) FI3532459T3 (pl)
HR (1) HRP20231369T1 (pl)
HU (1) HUE063848T2 (pl)
LT (1) LT3532459T (pl)
MD (1) MD3532459T2 (pl)
PL (1) PL3532459T3 (pl)
PT (1) PT3532459T (pl)
RS (1) RS64889B1 (pl)
SI (1) SI3532459T1 (pl)
SM (1) SMT202300381T1 (pl)
TW (1) TWI753037B (pl)
WO (1) WO2018081343A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3532459T2 (ro) 2016-10-26 2024-06-30 Constellation Pharmaceuticals Inc Inhibitori ai LSD1 și utilizările medicale ale acestora
SI3661510T1 (sl) 2017-08-03 2025-03-31 Oryzon Genomics, S.A. Postopki zdravljenja vedenjskih sprememb
US11649245B2 (en) 2018-09-13 2023-05-16 Helioeast Pharmaceutical Co., Ltd. Cyclopropylamine compound as LSD1 inhibitor and use thereof
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
US20220151998A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639273A (en) 1983-05-06 1987-01-27 Morton Thiokol, Inc. Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines
JP2656522B2 (ja) 1986-06-13 1997-09-24 ザ ルブリゾル コーポレーション リン含有の潤滑剤および機能流体組成物
US5188927A (en) 1990-06-15 1993-02-23 Fuji Photo Film Co., Ltd. Composition and process for the processing of silver halide color photographic material
WO1992017456A1 (fr) 1991-03-26 1992-10-15 Fujisawa Pharmaceutical Co., Ltd. Derive d'acide amine et sel dudit derive
US5344467A (en) 1991-05-13 1994-09-06 The Lubrizol Corporation Organometallic complex-antioxidant combinations, and concentrates and diesel fuels containing same
TW230781B (pl) 1991-05-13 1994-09-21 Lubysu Co
FR2687932A1 (fr) 1992-02-27 1993-09-03 Oreal Dispersion huile-dans-l'eau susceptible de former des films composites.
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
EP0678786B1 (en) 1994-04-19 1998-06-17 Agfa-Gevaert N.V. A method for making a lithographic printing plate
DE19523288A1 (de) 1995-06-27 1997-01-02 Basf Ag Iminooxybenzylverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
SE9600590D0 (sv) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
AR024378A1 (es) 1999-06-15 2002-10-02 Du Pont Pharm Co Gamma-carbolinas fusionadas heterociclicas sustituidas
UY26268A1 (es) 1999-08-06 2001-01-31 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
US7135437B2 (en) 2000-05-19 2006-11-14 Monsanto Technology Llc Stable liquid pesticide compositions
MY158895A (en) 2000-05-19 2016-11-30 Monsanto Technology Llc Potassium glyphosate formulations
WO2002000623A2 (en) 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US7008904B2 (en) 2000-09-13 2006-03-07 Monsanto Technology, Llc Herbicidal compositions containing glyphosate and bipyridilium
US6518444B1 (en) 2000-12-18 2003-02-11 Univation Technologies, Llc Preparation of polymerization catalysts
US20030096708A1 (en) 2001-03-02 2003-05-22 Monsanto Technology Llc Pesticide concentrates containing etheramine surfactants
DE60236428D1 (de) 2001-05-21 2010-07-01 Monsanto Technology Llc Etheramin-tenside enthaltende pestizidkonzentrate
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
JP2003064035A (ja) 2001-08-28 2003-03-05 Sony Corp 部分フッ化アルキル系化合物、該化合物からなる潤滑剤および該潤滑剤を用いた記録媒体
KR100577179B1 (ko) 2001-10-30 2006-05-10 엘지전자 주식회사 유기 전계 발광 소자
DE10302781B4 (de) 2002-02-23 2015-08-27 Merck Patent Gmbh Verfahren zur α,α-Difluoralkylierung von Stickstoffnucleophilen
AU2003249534A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2006503008A (ja) 2002-08-13 2006-01-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
FR2843750B1 (fr) 2002-08-23 2004-10-22 Cerep Composes derives d'arylcarbamates, preparation et utilisations
EP2292095A2 (en) 2002-08-31 2011-03-09 Monsanto Technology LLC Pesticide compositions containing a dicarboxylic acid or derivative thereof
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
JP4123361B2 (ja) 2002-12-11 2008-07-23 ライオン株式会社 漂白性組成物
ATE383325T1 (de) 2003-03-07 2008-01-15 Kawaken Fine Chemicals Co Verfahren zur herstellung von optisch aktivem alkohol in gegenwart von rhodium, einem chiralen ferrocenyldiphosphin und einem optisch aktivem diamin
US7678281B2 (en) 2003-07-18 2010-03-16 Bj Services Company Method of reclaiming brine solutions using an organic chelant
US7172703B2 (en) 2003-07-18 2007-02-06 Bj Services Co Method of reclaiming a well completion brine solutions using an organic chelant
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
JP4789966B2 (ja) 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
CN1942433A (zh) 2004-04-27 2007-04-04 北卡罗来纳查佩尔山大学 通过液相色谱法分离不对称二亚胺
US7285607B2 (en) 2004-05-18 2007-10-23 Sasol, Chemical Industries, Limited Polymerisation of olefinic compounds
WO2005118543A1 (ja) 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
ES2372474T3 (es) 2004-06-18 2012-01-20 Sasol Technology (Pty) Ltd Oligomerización en presencia tanto de un catalizador de tetramerización como de un catalizador de oligomerización adicional.
US8026237B2 (en) 2004-07-30 2011-09-27 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
FR2874010B1 (fr) 2004-08-04 2006-09-29 Rhodia Chimie Sa Procede d'acylation de composes nucleophiles notamment anilines
GB0421285D0 (en) 2004-09-24 2004-10-27 Univ Nottingham Improvements in high content screening
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
EP1809381A2 (en) 2004-10-06 2007-07-25 Recepticon ApS Use of compounds for the prevention of drug-induced cell toxicity
JP2009502959A (ja) 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
AR057451A1 (es) 2005-10-13 2007-12-05 Wyeth Corp Metodos para preparar derivados de acido glutamico
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007116011A2 (de) 2006-04-10 2007-10-18 Basf Se Substituierte triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
JP4771975B2 (ja) 2007-02-27 2011-09-14 三菱製紙株式会社 可逆性感熱記録材料
CN101622231B (zh) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
JP5511676B2 (ja) 2007-11-29 2014-06-04 メルク カナダ インコーポレイテッド 寄生虫疾患を治療するためのシステインプロテアーゼ阻害剤
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EP2285216A4 (en) 2008-02-21 2012-09-19 Sequoia Pharmaceuticals Inc HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
DE102008017215B4 (de) 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
CA2730749A1 (fr) 2008-07-18 2010-01-21 Sanofi-Aventis Nouveaux derives imidazo[1,2-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment commeinhibiteurs de met
JP5649779B2 (ja) 2008-11-28 2015-01-07 住友化学株式会社 液晶性組成物及び光学フィルム
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP2433940B9 (en) 2009-04-28 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
CA2760706C (en) 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
WO2010148652A1 (zh) 2009-06-26 2010-12-29 中国石油化工股份有限公司 柴油组合物及提高生物柴油氧化安定性的方法
ES2360783B1 (es) 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
JP2012077108A (ja) 2010-09-30 2012-04-19 Sumitomo Chemical Co Ltd ジハロビフェニル化合物及び該化合物の重合体
SG182932A1 (en) 2011-01-24 2012-08-30 Sumitomo Chemical Co Process for producing conjugated diene-based polymer, conjugated diene-based polymer, and conjugated diene-based polymer composition
EP3501546A3 (de) 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
JP6147730B2 (ja) 2011-04-27 2017-06-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 細胞を溶解する方法
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
DE102011079846B4 (de) 2011-07-26 2014-02-06 Merck Patent Gmbh Komplexverbindungen mit einem mehrzähnigen, asymmetrischen Liganden und ihre Verwendung im opto-elektronischen Bereich
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CN103906745B (zh) 2011-09-30 2017-08-25 塔夫斯大学 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
US9499474B2 (en) 2011-11-11 2016-11-22 Merck Patent Gmbh Process for producing arylamines
ES2904662T3 (es) 2012-05-09 2022-04-05 Sasol Tech Pty Ltd Oligomerización de compuestos olefínicos con formación reducida de polímeros
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
JP6523958B2 (ja) 2012-09-28 2019-06-05 タフツ・ユニバーシティ ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用
DE102012109685A1 (de) 2012-10-11 2014-04-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Umwandlung reaktiver Gruppen an Si-C-gebundenen Resten von Silanen unter gleichzeitiger Vergrößerung von deren räumlichem Abstand zueinander
WO2014065083A1 (ja) 2012-10-26 2014-05-01 コニカミノルタ株式会社 光学フィルム、円偏光板及び画像表示装置
KR101677866B1 (ko) 2012-10-29 2016-11-18 코니카 미놀타 가부시키가이샤 위상차 필름, 원편광판 및 화상 표시 장치
JP5902641B2 (ja) 2013-03-27 2016-04-13 富士フイルム株式会社 光干渉顔料およびその製造方法
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP2015030699A (ja) 2013-08-02 2015-02-16 マナック株式会社 アルカリ金属ハロゲン化物を用いたベンジルアミン類及びベンジルエーテル類の酸化的脱ベンジル化反応
FR3009309B1 (fr) 2013-08-02 2016-10-07 Total Marketing Services Compositions lubrifiantes pour transmissions
SG11201601199QA (en) 2013-08-19 2016-03-30 Univ Kingston Carbene-functionalized composite materials
KR102181235B1 (ko) 2013-08-30 2020-11-23 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102191991B1 (ko) 2013-09-06 2020-12-17 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102167042B1 (ko) 2013-09-06 2020-10-19 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR102191990B1 (ko) 2013-09-10 2020-12-17 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
KR20150091942A (ko) 2014-02-04 2015-08-12 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
WO2015126357A1 (en) 2014-02-18 2015-08-27 Renmatix, Inc. Method of reducing a fermentation and/or enzyme inhibitor in a saccharide-containing composition
US20150239918A1 (en) 2014-02-27 2015-08-27 Robert Lee Johnson Functionalized carbon matrix materials
WO2015133247A1 (ja) 2014-03-07 2015-09-11 独立行政法人産業技術総合研究所 カルバミン酸エステルの製造方法
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016123387A1 (en) * 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
MD3532459T2 (ro) * 2016-10-26 2024-06-30 Constellation Pharmaceuticals Inc Inhibitori ai LSD1 și utilizările medicale ale acestora
WO2018106984A1 (en) * 2016-12-09 2018-06-14 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors

Also Published As

Publication number Publication date
HUE063848T2 (hu) 2024-02-28
DK3532459T3 (da) 2023-10-30
RS64889B1 (sr) 2023-12-29
MD3532459T2 (ro) 2024-06-30
CN109863137A (zh) 2019-06-07
SI3532459T1 (sl) 2024-03-29
AU2017348100B2 (en) 2021-08-26
HRP20231369T1 (hr) 2024-02-16
US20190274998A1 (en) 2019-09-12
AU2017348100A1 (en) 2019-05-02
LT3532459T (lt) 2023-11-10
FI3532459T3 (fi) 2023-10-23
TW201821406A (zh) 2018-06-16
NZ752587A (en) 2025-09-26
CA3039793A1 (en) 2018-05-03
EP3532459B1 (en) 2023-08-02
PT3532459T (pt) 2023-11-10
TWI753037B (zh) 2022-01-21
ES2961499T3 (es) 2024-03-12
CN109863137B (zh) 2022-12-16
US10517849B2 (en) 2019-12-31
US20200306223A1 (en) 2020-10-01
US20220079917A1 (en) 2022-03-17
WO2018081343A1 (en) 2018-05-03
US11547695B2 (en) 2023-01-10
JP7142633B2 (ja) 2022-09-27
US11013718B2 (en) 2021-05-25
EP3532459A1 (en) 2019-09-04
JP2019537584A (ja) 2019-12-26
SMT202300381T1 (it) 2024-01-10

Similar Documents

Publication Publication Date Title
IL271999A (en) TYK2 inhibitors and uses thereof
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
EP3344624B8 (en) Tyk2 inhibitors and uses thereof
IL262387B (en) Arginase inhibitors and treatment applications thereof
GB201605126D0 (en) Inhibitors and their uses
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
EP3262049A4 (en) Tyk2 inhibitors and uses thereof
HUE063848T2 (hu) LSD1 gátlók és gyógyászati alkalmazásaik
PL3240777T3 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
HUE059778T2 (hu) URAT1-inhibitor és alkalmazása
SMT202300256T1 (it) Inibitori di lrrc33 e loro uso
IL267238A (en) The paranase inhibitors and their use
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL254916B (en) Inhibitors and their uses
ZA201803212B (en) Gelatinase inhibitors and use thereof
IL267243A (en) The paranase inhibitors and their use
SG11201707282RA (en) Kv1.3 inhibitors and their medical application
ZA201808008B (en) Arginase inhibitors and their therapeutic applications
HK40012789A (en) Tyk2 inhibitors and uses thereof
GB2545167B (en) Cloches and use thereof
GB201709837D0 (en) Methods and medical uses
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses
GB201504770D0 (en) Medical devices and methods